AC
ACHV.US Achieve Life Sciences Inc
- Market cap
- USD 746M
- P/E
- -
- P/B
- 3.93x
- ROE
- -71.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ACHV.US undervalued?
Graham numberThe Graham number of Achieve Life Sciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Achieve Life Sciences Inc fundamental analysis
No fundamental analysis for Achieve Life Sciences Inc yet.
Achieve Life Sciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is he…
Full company profileAchieve Life Sciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Achieve Life Sciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 152K |
| Gross Profit | 5.06M | -282K | -282K | -254K | -255K | -250K | -236K | -228K | -229K | -228K | - |
| Operating Income | -21.2M | -6.63M | -12.8M | -16.5M | -14.8M | -33.1M | -40.8M | -27.3M | -39.1M | -54.9M | -65.9M |
| EBITDA | -19.9M | -13.4M | -12.5M | -16.3M | -14.5M | -32.8M | -40.6M | -26.7M | -37.4M | -53.6M | -140M |
| Net Income | -20.1M | -10.6M | -12.7M | -16.1M | -14.7M | -32.9M | -41.9M | -29.8M | -39.8M | -54.6M | -129M |
| EPS | -1,475 | -441 | -72 | -39 | -5.39 | -4.05 | -3.95 | -1.50 | -1.24 | -1.25 | -1.53 |
| Balance Sheet | |||||||||||
| Total Assets | 27.5M | 9.89M | 19.1M | 21.1M | 40.3M | 47.5M | 30.0M | 19.4M | 38.6M | 41.8M | 206M |
| Total Liabilities | 8.50M | 2.01M | 3.28M | 3.03M | 3.01M | 19.5M | 21.7M | 20.8M | 17.7M | 20.3M | 25.7M |
| Shareholders' Equity | 19.0M | 7.88M | 15.8M | 18.1M | 37.3M | 28.0M | 8.30M | -1.45M | 20.9M | 21.5M | 181M |
| Cash & Short-term Investments | 25.7M | 5.28M | 14.7M | 16.7M | 35.9M | 43.0M | 24.7M | 15.5M | 34.3M | 36.4M | 202M |
| Total Debt | 106K | 27.0K | 35.0K | 362K | 169K | 15.0M | 16.2M | 16.7M | 9.96M | 15.0M | 14.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -29.7M | -9.11M | -10.6M | -15.2M | -13.5M | -29.4M | -37.6M | -24.5M | -29.8M | -49.5M | -34.8M |
| Capital Expenditure | 46.0K | 46.0K | 46.0K | 53.0K | 17.0K | 17.0K | 0.00 | 21.0K | 0.00 | 3.00K | 65.3K |
| Free Cash Flow | -29.7M | -9.11M | -10.7M | -15.3M | -13.5M | -29.4M | -37.6M | -24.5M | -29.8M | -49.5M | -34.8M |
| Ratios | |||||||||||
| ROE | -106.1% | -134.3% | -80.3% | -89.4% | -39.3% | -117.3% | -504.3% | - | -190.6% | -254.0% | -71.6% |
| ROA | -73.3% | -107.0% | -66.5% | -76.6% | -36.4% | -69.2% | -139.7% | -153.9% | -103.1% | -130.8% | -62.7% |
| Net Profit Margin | -397.6% | - | - | - | - | - | - | - | - | - | -85,128.9% |
| Debt to Equity | 0.01x | 0.00x | 0.00x | 0.02x | 0.00x | 0.53x | 1.95x | - | 0.48x | 0.69x | 0.08x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Achieve Life Sciences Inc dividends
Achieve Life Sciences Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Jul 31, 2020.
Who owns Achieve Life Sciences Inc
- Insiders 0.85%
- Institutions 80.65%
- Public & others 18.50%
- Shares outstanding 110M
- Free float 87.2M
Top funds holding ACHV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.42M | 2.34% | -22.25% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.25M | 2.18% | +2.69% | Oct 2026 |
| Eventide Healthcare & Life Sciences I | 2.22M | 2.15% | 0.00% | Jun 2026 |
| iShares Russell 2000 ETF | 1.98M | 1.92% | 0.00% | Oct 2026 |
| Franklin Biotechnology Discv A(acc)USD | 1.93M | 1.87% | 0.00% | Sep 2026 |
| JPMorgan Small Cap Growth A | 1.72M | 1.67% | 0.00% | Sep 2026 |
| Franklin Biotechnology Discovery A | 1.10M | 1.06% | 0.00% | Sep 2026 |
| Simplify Propel Opportunities ETF | 932K | 0.90% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 852K | 0.83% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 743K | 0.72% | -0.38% | Oct 2026 |
| JPMorgan Small Cap Blend A | 555K | 0.54% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 452K | 0.44% | +1.11% | Sep 2026 |
| Fidelity Extended Market Index | 410K | 0.40% | +0.87% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 309K | 0.30% | +0.27% | Oct 2026 |
| BNY Mellon Sm/Md Cp Gr I | 251K | 0.24% | -4.56% | Sep 2026 |
| iShares Micro-Cap ETF | 235K | 0.23% | 0.00% | Oct 2026 |
| Multi-Manager Small Cap Eq Strat Inst | 218K | 0.21% | 0.00% | Sep 2026 |
| Invesco Dorsey Wright SmallCap Momt ETF | 195K | 0.19% | -0.54% | Oct 2026 |
| Vanguard US Momentum Factor ETF | 193K | 0.19% | 0.00% | Sep 2026 |
| Schwab Small Cap Index | 189K | 0.18% | 0.00% | Sep 2026 |
Top institutions holding ACHV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 7.61M | 7.39% | 0.00% | Jun 2026 |
| TPG GP A, LLC | 6.88M | 6.67% | 0.00% | Jun 2026 |
| venBio Partners LLC | 5.91M | 5.74% | 0.00% | Jun 2026 |
| Logos Global Management LP | 5.43M | 5.26% | 0.00% | Jun 2026 |
| BlackRock Inc | 5.27M | 5.11% | +1,099.93% | Jun 2026 |
| Franklin Templeton Inc | 4.95M | 4.80% | +13.37% | Jun 2026 |
| Paradigm Biocapital Advisors LP | 4.95M | 4.80% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.14M | 4.02% | +87.82% | Jun 2026 |
| Propel Bio Management LLC | 4.03M | 3.91% | +6.54% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 3.77M | 3.66% | +269.90% | Jun 2026 |
| State Street Corp | 2.95M | 2.86% | +1,057.57% | Jun 2026 |
| Vivo Capital, LLC | 2.75M | 2.67% | 0.00% | Jun 2026 |
| VR Adviser, LLC | 2.75M | 2.67% | 0.00% | Jun 2026 |
| Jupiter Topco LLC | 2.75M | 2.67% | 0.00% | Jun 2026 |
| Eventide Asset Management, LLC | 2.22M | 2.15% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 2.06M | 2.00% | +231.21% | Jun 2026 |
| Alyeska Investment Group, L.P. | 1.93M | 1.87% | 0.00% | Jun 2026 |
| Wellington Management Company LLP | 1.43M | 1.38% | 0.00% | Jun 2026 |
| Simplify Asset Management Inc. | 932K | 0.90% | -34.91% | Sep 2026 |
| LPL Financial Corp | 902K | 0.88% | +23.86% | Jun 2026 |
Achieve Life Sciences Inc company profile
- Company name
- Achieve Life Sciences Inc
- Ticker
- ACHV.US
- Exchange
- USA Stocks
- Listed since
- Oct 13, 1995
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 28
- Fiscal year end
- December
- Address
- 22722 29th Dr. SE, Bothell, WA, United States, 98021
- Phone
- 604 210 2217
- Website
- achievelifesciences.com
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Achieve Life Sciences Inc management
9- Mr. Erik AtkissonChief Legal Officer · born 1972
- Mr. Benjamin Halladay M.B.A.Chief Financial Officer · born 1986
- Mr. Jerry WanVP of Finance & Principal Accounting Officer · born 1982
- Ms. Kaitlyn TusonSenior Vice President of Marketing & Communications
- Dr. Mark L. Rubinstein M.D.Chief Medical Officer · born 1968
- Mr. Mark ZappiaSenior Vice President of Commercial
- Mr. Ronald DadinoSenior Vice President of Chemistry, Manufacturing & Controls and Supply Chain
- Ms. Gloria CosgroveSenior Vice President of Global Quality
- Ms. Nicole P. JonesVice President of Strategic Communications & Stakeholder Relations